Expert Tips and Cancer Resources

A year to remember: Advancements, recognition and transitions

12/20/2024

Catch the 2024 highlights from Providence Cancer Institute in this year-end recap focused on research advancements, caregiver recognition and community engagement.

CAR T cell-therapy, hope and healing: Dean’s story

12/20/2024

Discover how Dean Lookingbill’s battle with lymphoma led him to CAR T-cell therapy at Providence Cancer Institute.

Two clinical trials for solid tumor cancers take different approaches to stop growth

11/22/2024

Two global studies open at Providence Cancer Institute will evaluate combinations of medications to help stop or slow the growth of cancer in solid tumors.

Comprehensive Genomic Profiling leads to better patient outcomes, new joint study says  

Real-world data from Providence, Illumina and Microsoft Research finds cancer patients with early genomic testing received better precision treatment, underlines urgency to become standard practice

Leadership change at Providence Cancer Institute, #FINISHCANCER goal remains

11/14/2024

R. Bryan Bell, M.D., D.D.S., FACS, FRCS(Ed) has accepted the roles of executive medical director of Providence Cancer Institute and director of the Earle A. Chiles Research Institute.

2024 SITC Meeting: A glimpse of recent advancements in immunotherapy

11/19/2024

The annual SITC meeting brings together cancer immunotherapy researchers with a goal to advance science, discover breakthroughs and educate the world on cancer immunotherapy.

Harnessing CAR T-cell therapy: A new study for indolent B-cell non-Hodgkin lymphoma

10/30/2024

New study evaluates a type of CAR T-cell therapy called liso-cel. Researchers will collect data from multiple groups in a study that may give patients hope for long-term remission and quality of life.

New studies test immunotherapy to boost breast cancer treatment and prevent return

10/30/2024

Explore promising clinical trials at Providence Cancer Institute that are investigating immunotherapy for early-stage TNBC and high-risk, HR-positive breast cancer.

Attend a free virtual symposium on melanoma, Oct. 25

10/8/2024

Providence Cancer Institute in partnership with AIM at Melanoma present a free online event designed to educate and empower patients and care partners affected by melanoma.

Prostate cancer study includes a tumor test to personalize treatment

9/27/2024

A new study approach reflects a deeper understanding of cancer at the molecular level and marks a shift away from one-size-fits-all treatments.

Meet physician scientist, Dr. Allie Grossmann

9/23/2024

Dr. Allie Grossmann’s new lab at Earle A. Chiles Research Institute is focused on understanding how tumors communicate with their environment, grow, survive and spread.

Dr. Walter Urba announces retirement from Providence

8/22/2024

Dr. Walter Urba, a pioneer and key figure in the development of immunotherapy, will retire from Providence Cancer Institute at the end of year.

Dr. Bernard Fox honored for his lifetime contributions to cancer research

8/23/2024

Prominent cancer scientist Dr. Bernard Fox recognized for his work to advance the field of cancer immunotherapy through increasing public understanding, awareness and research efforts.

Can these new studies offer hope for people with lung and head and neck cancers?

8/27/2024

A new medication may help people with KRAS G12C-mutant non-small cell lung cancer. Read about the study and a trial evaluating an immunotherapy for treating head and neck squamous cell carcinoma.

Cancer survivor speaks with doctor he credits for saving his life

8/27/2024

Cancer survivor Mark Williams chats with Dr. Brendan Curti about

2024 Hood to Coast Relay: Providence team captains tell us why they run

8/22/2024

What motivates the co-captains of the FINISHCANCER caregiver team to commit their time to running this remarkable relay? Read what they say about preparing for the race and what inspires them to run.

Promising advances in treating TNBC: Two studies offer hope

7/31/2024

Although chemotherapy is the cornerstone treatment for triple negative breast cancer, survival outcomes remain disappointing. Two studies could help improve treatment options.

Targeting cancer cells: Two studies take different approaches

6/26/2024

A study designed to treat recurrent epithelial ovarian cancer looks at an antibody drug conjugate, and a second study for people with advanced breast cancer evaluates a drug that degrades estrogen rec

The evolution of cancer immunotherapy: Dr. Urba shares his insights

6/28/2024

Providence Cancer Institute chief medical officer Walter J. Urba, M.D., Ph.D. talks about the evolution of immunotherapy in the past three decades and his vision for its future.

Cancer survivorship: A guide to living with and beyond cancer

6/11/2024

June is National Cancer Survivor Month, but we honor people with cancer, no matter where they are on their journey, every day of the year. Find out about the survivorship program at Providence Cancer

Radiation oncologist discusses MRI-guided radiation therapy for pancreatic cancer

8/9/2024

Providence Cancer Institute presented a free virtual education event about MRI-guided radiation therapy and how it is used to treat pancreatic cancer.

Providence researchers contribute study findings at ASCO 2024 meeting, May 31- June 3

6/10/2024

The annual meeting of cancer experts is a platform to collaborate and accelerate cancer research findings into clinical applications.

With the potential to transform cancer diagnostics, Providence contributes to innovative AI-powered digital pathology model

6/3/2024

A joint study between Providence, Microsoft and the University of Washington detailing work to create a novel AI-powered pathology model has been published in Nature.

Covenant Health Earns APEx Accreditation for Radiation Oncology Services

5/21/2024

The radiation oncology team at Joe Arrington Cancer Center is awarded APEx Accreditation for excellent care.

Cancer studies seek to harness the power of the immune system

5/29/2024

Explore three innovative studies targeting uveal melanoma, melanoma and head and neck squamous cell carcinoma. Learn why these studies offer hope for more effective cancer treatments.

Providence Regional Cancer System Patient Navigator Focuses on Head and Neck Cancers

5/9/2024

Patient Navigators provide a wealth of information and support to patients and families at all three Providence oncology locations: Lacey, Centralia and Aberdeen.